Background We assessed outcome of patients with moderate and severe COVID-19
following treatment with convalescent plasma (CP) and the association with IgG levels in …

Objectives The coordinated immune response of the host is the key of the successful combat
of the body against SARS-CoV-2 infection and is decisive for the development and …

Objectives The potential benefit of convalescent plasma (CP) therapy for coronavirus
disease 2019 (COVID-19) is highest when administered early after symptom onset. Our …

Plasma provided by COVID‐19 convalescent patients may provide therapeutic relief as the
number of COVID‐19 cases escalates steeply worldwide. Prior findings in various viral …

The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled …

The COVID-19 is currently spreading around the world, which has posed significant threats
to global health and economy. Convalescent plasma is confirmed effective against the novel …

Importance Convalescent plasma is a potential therapeutic option for patients with
coronavirus disease 2019 (COVID-19), but further data from randomized clinical trials are …

COVID-19 has become one of the worst infectious disease outbreaks of recent times, with
over 2.1 million cases and 120,000 deaths so far. Our study investigated the demographic …

The outbreak of coronavirus disease 2019 (COVID-19), caused by the novel coronavirus
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a threat to …

BACKGROUND COVID-19 convalescent plasma (CCP) has been considered a treatment
option for COVID-19. This trial assessed the efficacy of a neutralizing antibody containing …